LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA)

TargetMol
Product Code: TAR-TP2147
Supplier: TargetMol
CodeSizePrice
TAR-TP2147-100mg100mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2147-50mg50mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2147-5mg5mg£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2147-10mg10mg£164.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2147-25mg25mg£257.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Further Information

Bioactivity:
LSKL, Inhibitor of Thrombospondin (TSP-1) TFA, a latency-associated protein (LAP)-TGFβ derived tetrapeptide, is a competitive antagonist of TGF-β1.
CAS:
TP2147
Formula:
C23H43F3N6O7
Molecular Weight:
572.62
Purity:
0.98
SMILES:
0

References

Laurent MA, et al. In silico characterization of the interaction between LSKL peptide, a LAP-TGF-beta derived peptide, and ADAMTS1. Comput Biol Chem. 2016 Apr;61:155-61. Liao F, et al. LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-?1 signaling activity following subarachnoid hemorrhage in rats. Exp Ther Med. 2016 Oct;12(4):2537-2543. Epub 2016 Aug 31. Kuroki H, et al. Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor ? signal activation and liver regeneration after hepatectomy in an experimental model. Br J Surg. 2015 Jun;102(7):813-25.